Novo Nordisk Pharmatech has announced it will be showcasing its innovative biologics and Insulin Human AF at the World Biosimilar Congress in Switzerland.

To be held from 31 October to 1 November at Congress Center Basel, the congress is a commercially focused event bringing together the full value chain. It looks at commercialising and pushing forward adoption of biosimilars globally.

Novo Nordisk Pharmatech invites you to visit booth #53 to discover more about recombinant insulin for innovative biologics and Insulin Human AF.

Novo Nordisk Pharmatech is one of the leading worldwide suppliers of recombinant insulin. A key component in serum-free growth media for mammalian cells, the company’s recombinant insulin products are approved by regulatory bodies worldwide, including the US Food and Drink Administration (FDA) and European Medicines Agency (EMA). Its products are manufactured to current good manufacturing practice (cGMP) standards and the company guarantees:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

Novo Nordisk Pharmatech delivers a proven record of product purity, reliability, and consistency, as well as custom quality products for future therapies.